{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"69.9","upperLimit":"83.2","value":"77.4"},{"groupId":"OG001","lowerLimit":"59.6","upperLimit":"74.5","value":"67.7"},{"groupId":"OG002","lowerLimit":"64.3","upperLimit":"78.7","value":"72.2"},{"groupId":"OG003","lowerLimit":"66.1","upperLimit":"80.1","value":"73.9"}]}],"title":"24 Months (n=167, 167, 168, 168)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"58.3","upperLimit":"73.6","value":"66.6"},{"groupId":"OG001","lowerLimit":"45.4","upperLimit":"61.8","value":"54.0"},{"groupId":"OG002","lowerLimit":"59.2","upperLimit":"74.5","value":"67.5"},{"groupId":"OG003","lowerLimit":"54.3","upperLimit":"70.1","value":"62.8"}]}],"title":"36 Months (n=167, 167, 168, 168)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"50.6","upperLimit":"66.6","value":"59.1"},{"groupId":"OG001","lowerLimit":"39.4","upperLimit":"56.2","value":"48.0"},{"groupId":"OG002","lowerLimit":"54.8","upperLimit":"70.7","value":"63.3"},{"groupId":"OG003","lowerLimit":"50.1","upperLimit":"66.3","value":"58.7"}]}],"title":"48 Months (n=167, 167, 168, 168)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"43.8","upperLimit":"60.5","value":"52.5"},{"groupId":"OG001","lowerLimit":"35.5","upperLimit":"52.5","value":"44.2"},{"groupId":"OG002","lowerLimit":"49.8","upperLimit":"66.5","value":"58.7"},{"groupId":"OG003","lowerLimit":"43.7","upperLimit":"60.5","value":"52.5"}]}],"title":"60 Months (n=167, 167, 168, 168)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"39.2","upperLimit":"56.2","value":"40.0"},{"groupId":"OG001","lowerLimit":"30.6","upperLimit":"47.7","value":"39.2"},{"groupId":"OG002","lowerLimit":"43.7","upperLimit":"61.1","value":"52.8"},{"groupId":"OG003","lowerLimit":"38.7","upperLimit":"56.0","value":"47.7"}]}],"title":"72 Months (n=167, 167, 168, 168)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"33.4","upperLimit":"50.6","value":"42.1"},{"groupId":"OG001","lowerLimit":"29.6","upperLimit":"46.7","value":"38.2"},{"groupId":"OG002","lowerLimit":"34.5","upperLimit":"52.9","value":"43.9"},{"groupId":"OG003","lowerLimit":"34.5","upperLimit":"52.1","value":"43.5"}]}],"title":"84 Months (n=167, 167, 168, 168)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"167"},{"groupId":"OG001","value":"167"},{"groupId":"OG002","value":"168"},{"groupId":"OG003","value":"168"}],"units":"Participants"}],"description":"PFS= time from randomization until: CHR achieved and participant subsequently no longer met criteria for CHR over 2 weeks; no CHR after receiving maximum dose and an increase in WBC (ie, doubling of the count from the lowest value to \\> 20,000/mm\\^3 or an increase by \\> 50,000/mm\\^3 on 2 assessments performed 2 weeks apart); participant met criteria of accelerated phase or blast phase CML; participant had MCyR and subsequently no longer met criteria for MCyR after starting maximum dose; participant had a ≥ 30% absolute increase in number of Ph+ metaphases. Deaths without a reported prior progression were considered to have progressed on the date of death; those who neither progressed nor died were censored on the date of their last cytogenetic or hematologic assessment. When first progression reported during follow-up, it was censored at last on-study assessment. If the first progression reported during follow-up was death, participant considered to have progressed at date of death.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 100 mg once a day (QD) until progression of disease, development of intolerable toxicity, or the participant's decision to withdraw.\n\nAfter the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.","id":"OG000","title":"Dasatinib 100 mg QD"},{"description":"Participants received 140 mg QD until progression of disease, development of intolerable toxicity, or the participant's decision to withdraw. After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.","id":"OG001","title":"Dasatinib 140 mg QD"},{"description":"Participants received 50 mg twice a day (BID) until progression of disease, development of intolerable toxicity, or the participant's decision to withdraw. After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.","id":"OG002","title":"Dasatinib 50 mg BID"},{"description":"Participants received 70 mg BID until progression of disease, development of intolerable toxicity, or the participant's decision to withdraw. After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.","id":"OG003","title":"Dasatinib 70 mg BID"}],"paramType":"NUMBER","populationDescription":"All participants who were randomized to a treatment arm were summarized.","reportingStatus":"POSTED","timeFrame":"24, 36, 48, 60, 72, and 84 months","title":"Percent of Participants With Progression Free Survival (PFS) at 24, 36, 48, 60, 72, and 84 Months Follow-Up by Dose Schedule and Total Daily Dose - All Randomized Participants","type":"SECONDARY","unitOfMeasure":"percentage of participants"}